Connecticut, Missouri, and New Hampshire join 10 other states considering psychedelics bills.

States so far include Alaska, Arizona, California, Hawaii, Indiana, Illinois, Massachusetts, Maryland, New Jersey, and Wisconsin.

The FDA may receive a new drug application as early Q3 of 2023.

Across the nation, not only is marijuana growing more accepted, but so are other drugs like psilocybin and MDMA.

Phase 3 studies are underway, and current research sees potential for MDMA in psychotherapy.

Our Chief Medical Officer and VP of Clinical Services comment on the clinical use of ecstasy and marijuana.